Message #2 From:
NewsBot Date: February 26, 2007 02:00:00 PM
PKI News PerkinElmer Announces New Analytical Solutions and Services at PITTCON(R) 2007
CHICAGO--(BUSINESS WIRE)--PerkinElmer, Inc. (NYSE: PKI), a global leader in Health Sciences and Photonics, is introducing its latest analytical solutions at PITTCON® 2007, February 26-March 2. The new offerings are designed to help scientists advance the pace and precision of research and testing in a wide range of market segments including environmental, hydrocarbon processing and biofuels, forensics, food and beverage, pharmaceuticals, and chemical quality control.
"Our product development efforts are focused in two areas – tailoring our solutions to specific customer applications to drive increased productivity, and expanding the breadth of our technologies and services," said Robert F. Friel, president of PerkinElmer Life and Analytical Sciences. "The new products being introduced at this year’s Pittsburgh Conference are excellent examples of how we are delivering on this strategy."
The new, application-focused solutions that are being showcased include:
The new Clarus®600 Gas Chromatograph (GC) and Clarus® 600 Gas Chromatograph/Mass Spectrometer (GC/MS) with novel oven technology enabling the fastest injection-to-injection time in a conventional GC while reducing cycle time and significantly increasing sample throughput. The Clarus 600 GC was designedfor the full spectrum of GC users, including environmental, independent testing, forensics, petrochemicals and chemical quality-control laboratories. The new family of Clarus 600 GC/MS is powered by the novel oven, delivers best-in-class performance and supports the same segments as the Clarus 600 GC, along with applications for food and fragrance analysis.
Other GC innovations include four Biodiesel Gas Chromatography Turnkey Systems that provide the rapidly growing biofuels industry with high-quality analyzers for the verification of pure biodiesel to meet ASTM and European standards.
The new qVisc 4320 AX Autosampler Viscometer, now available from PerkinElmer under a distribution agreement with The Fluid Life Corporation, expands PerkinElmer’s used oil analysis solutions and delivers unprecedented throughput and automation.
The new Spectrum™ 400 is the latest infrared tool to combine optimized near-infrared (NIR) and optimized mid-infrared (MIR) spectroscopy in a single research-grade instrument with push-button switching for troubleshooting, method and product development and routine analyses in the chemicals and materials, pharmaceutical and academic segments.
The RamanStation™ 400, PerkinElmer’s first in a series of new Raman instrumentation, offers unprecedented ease-of-use, allowing faster data collection, more uptime and greater reproducibility for users in academia and drug discovery.
Other new products and services include:
Spectrum™Express Software– An easy-to-use software program for the Spectrum family of instruments that allows users to complete analyses faster with minimal user training needed. Users in the chemicals and materials, pharmaceutical and academic segments simply “walk up and measure.”
DMA 8000– An easy-to-use, flexible and powerful Dynamic Mechanical Analyzer (DMA) for thermal analysis of materials’ bulk properties for the polymers, composites, pharmaceutical and food industries.
Improved Workflow Management features for LABWORKS™ LIMS 6.0– A new graphical workflow editor for tailoring and testing changes to the default workflow.
PerkinElmer SCIEX™ELAN®v3.4 Software– Fully automated and easy-to-use software for Inductively Coupled Plasma Mass Spectrometry (ICP-MS) helps increase consistency of performance and efficiencies for high-productivity laboratories including environmental, chemical and geochemical laboratories, and laboratories in the food, nutrition and semiconductor industries.
OneSource® Laboratory Services– Representatives from PerkinElmer’s proven laboratory management and maintenance solution will be on-hand to provide information on its recently expanded offerings, including its new laboratory relocation service and enhanced multi-vendor support capabilities.
This press release contains “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to estimates and projections of future earnings per share and revenue growth and other financial results, developments relating to our customers and end-markets, and plans concerning business development opportunities. Words such as “believes,”“intends,”“anticipates,”“plans,”“expects,”“projects,”“forecasts,”“will” and similar expressions, and references to guidance, are intended to identify forward-looking statements. Such statements are based on management’s current assumptions and expectations and no assurances can be given that our assumptions or expectations will prove to be correct. A number of important risk factors could cause actual results to differ materially from the results described, implied or projected in any forward-looking statements. These factors include, without limitation: (1) our failure to introduce new products in a timely manner; (2) our ability to execute acquisitions and license technologies, or to successfully integrate acquired businesses and licensed technologies into our existing business or to make them profitable; (3) our failure to protect adequately our intellectual property; (4) the loss of any of our licenses or licensed rights; (5) our ability to compete effectively; (6) fluctuation in our quarterly operating results and our ability to adjust our operations to address unexpected changes; (7) our ability to produce an adequate quantity of products to meet our customers’ demands; (8) our failure to maintain compliance with applicable government regulations; (9) regulatory changes; (10) economic, political and other risks associated with foreign operations; (11) our ability to retain key personnel; (12) restrictions in our credit agreement; (13) our ability to realize the full value of our intangible assets; and (14) other factors which we describe under the caption “Risk Factors” in our most recent annual report on Form 10-K and in our most recent quarterly report on Form 10-Q and in our other filings with the Securities and Exchange Commission. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.
Other Information
Health Sciences end markets include genetic screening, environmental, service, biopharma, and medical imaging. Photonics markets include sensors and specialty lighting.
PerkinElmer, Inc. is a global technology leader driving growth and innovation in Health Sciences and Photonics markets to improve the quality of life. The Company reported revenues of $1.55 billion in 2006, has 8,500 employees serving customers in more than 125 countries, and is a component of the S&P 500 Index.Additional information is available through www.perkinelmer.com or 1-877-PKI-NYSE.
